The feasibility of implementing current medication treatment guidelines in a community mental health clinic was examined in this cross-sectional and retrospective study. Specifically, two issues were addressed: 1) could we identify a set of clinical guidelines whose utilization could be monitored with a routine medical chart review; and 2) were the requisite data for such a review available in the medical records. An examination of three sets of published guidelines revealed 5 specific guidelines that could be operationalized and monitored. Records were reviewed for a random sample of two-thirds of all patients currently diagnosed with schizophrenia and schizoaffective disorder (n = 309). Information was collected from the medical record on patient demographics, diagnosis, duration of illness, symptoms and side effects, and medication information. Rates of conformance to the 5 guidelines ranged from a high of 97% to a low of 43%. The use of current guidelines to improve treatment in community clinics appears to be limited by the deficiencies in the medical record and the structure of the guidelines themselves. Standardized progress notes and computerized prescribing
INTRODUCTION
The introduction of the atypical antipsychotics ushered in a new era in the treatment of schizophrenia. They offer a broader spectrum of efficacy with decreased risk for movement disorders and the promise of increased patient compliance (Jibson and Tandon, 1998) . However, because the cost of the newer antipsychotics is higher than that of the older conventional antipsychotics (DeQuardo and Tandon, 1998) , decisions regarding the allocation of limited resources have to be raised (Doherty, 1999) . To ensure that treatment decisions are rational and evidence-based, professional and government agencies have published clinical practice guidelines and algorithms for the treatment of severe mental illnesses (American Psychiatric Association, 1997; Lehman and Steinwachs, 1998a; The Expert Consensus Guideline Series, 1999; Chiles, Miller, Crismon, Rush, Krasnoff, and Shon, 1999) . We examined the feasibility of operationalizing guidelines and monitoring the use of medication treatment guidelines in a CMHC. Specifically, we reviewed three national guidelines and algorithms for schizophrenia (Lehman and Steinwachs, 1998a; The Expert Consensus Guideline Series, 1999; Chiles, Miller, Crismon Rush, Krasnoff, and Shon, 1999) and identified a set of maintenance treatment recommendations that could be assessed using data available in a cross-sectional, retrospective chart review. We then examined the extent to which current pharmacological treatment practice at the CMHC conformed to those recommendations.
METHODS
The study was conducted in a small urban CMHC in the Midwest affiliated with a large university academic medical center. Three hundred and nine patients aged 18 years of age and older and diagnosed with schizophrenia or schizoaffective disorder, selected randomly from the center's data bank, comprised the study sample. A trained research assistant, using a data abstraction form designed for the study, conducted medical record reviews. Data were collected on patient demographics, diagnosis, duration of illness, symptoms and side effects, and medication.
We reviewed the recommendations for maintenance pharmacological treatment of schizophrenia in three sets of national guidelines: the Patient Outcomes Research Team (PORT) for schizophrenia (Lehman and Steinwachs, 1998a) , the Texas Medication Algorithm Project (TMAP; Chiles, Miller, Crismon, Rush, Krasnoff, and Shon 1999) , and the Expert Consensus Guideline series (1999) . We identified five recommendations that could be evaluated using a cross-sectional medical chart review, and for which the required information was available in at least 50% of the medical records. Each recommendation was translated into a conformance criterion, which was then applied to current practices to estimate a conformance rate (Agency for Health Care Policy and Research, 1995) .
The first guideline suggests that persons with schizophrenia or schizoaffective disorder who experience acute symptom relief with an antipsychotic should continue to receive this medication for at least one year. Given the constraints of the available data, the compliance criterion we assessed was whether individuals with these diagnoses were being prescribed an antipsychotic medication.
A second guideline recommends that the maintenance dosage of antipsychotic medication be in the range of 300-600 mg chlorpromazine (CPZ) equivalents per day. Our crosssectional data could not be used to determine whether a patient's current medication was prescribed for acute or maintenance treatment. However, since more than 80% of the sample had been ill for at least 10 years, we assumed that most patients were on maintenance doses and created a conformance criterion that assessed whether the antipsychotic dosages prescribed for patients were between 300-600 mg CPZ equivalents/day. Only those patients prescribed one oral antipsychotic medication were included in the assessment.
The PORT study advises that patients with severe TD be offered a trial of clozapine, while Consensus guidelines recommend that patients with mild TD be switched to risperidone or vitamin E be added to their current antipsychotic treatment. To operationalize these recommendations, we defined severe TD as an AIMS score of ≥3, indicating that the patient had minimal abnormal movements in at least three parts of the body or mild to moderate movements in at least one. Mild TD was defined as an AIMS score of one or two.
A fourth guideline recommends that persons who experience persistent, clinically significant positive symptoms despite adequate antipsychotic therapy receive a trial of two or more antipsychotics, adjunctive pharmacotherapy, or clozapine. Since our crosssectional methodology provided no information on the use, duration, or outcome of previous medication trials, we drafted a conformance criterion that examined whether patients with positive symptoms noted in their medical record were receiving one or more of the above-recommended treatments.
The PORT guidelines recommend an "ongoing assessment" of the effectiveness/need for maintenance antipsychotic therapy and anti-parkinsonian agents. The Consensus guidelines specifically recommended monthly clinic visits for compliant, asymptomatic patients and evaluations for TD at a minimum of twice a year. The conformance criterion we used was whether patients had a clinic visit within four weeks of the chart review, and an AIMS test within three months (reflecting the CMHC's own higher standard for TD assessments).
RESULTS

Sample Characteristics
Of the 309 subjects, 43% were female; 64% were Caucasian and 30% were African-American. Mean (SD) age was 46.4 (11.9) years (range: 20-86 years). Eighty-one percent were diagnosed with schizophrenia; 19% with schizoaffective disorder. Mean (SD) duration of illness was 21.1 (11.4) years. Mean (SD) score on the Global Assessment of Functioning (GAF) scale was 49.3 (9.5).
Medical Record Review
Much of the clinical information needed to assess guideline conformance was not documented in the medical record. For example, while the presence or absence of positive symptoms was noted in three-quarters of the charts, the presence or absence of negative symptoms was documented in only 6% (18). This lack of information limited the number of guidelines that could be evaluated.
Conformance to Guidelines
Conformance rates for the five criteria are listed below:
Criterion 1: 299 (96.8%) of this sample were being treated with an antipsychotic. Criterion 2: Of the 179 prescriptions for monotherapy antipsychotic treatment, 43% were within the recommended dose range of 300-600 mg CPZ equivalents/day; 26% were below, and 32% were above (Table 1) . Criterion 3: Of the forty-six patients identified with severe TD, 63.0%
were being treated with an atypical antipsychotic (23.9% with clozapine). Just over one-third (36.4%) of those with mild TD received either an atypical antipsychotic and/or vitamin E. Criterion 4: Information regarding the presence or absence of positive symptoms was noted in the medical charts for 224 subjects; positive symptoms were present in 83 and absent in 141. Of those with positive symptoms, 70 (84.3%) were receiving at least one of the recommended treatments. Criterion 5: Just over one-half (54.4%) of the subjects had a clinic visit within four weeks of data collection; similarly just over half (54.0%) had an AIMS test within the past three months.
DISCUSSION
Nearly all patients (97%) in our study were prescribed an antipsychotic medication. In an evaluation of the PORT guidelines, Lehman and Stein- 
Number of Patients with Schizophrenia or Schizoaffective Disorder Currently Prescribed an Antipsychotic at a Dose of 300-600 mg Chlorpromazine Equivalents/day
Guideline 2 The maintenance dosage of antipsychotic medication should be in the range of 300-600 mg chlorpromazine (CPZ) equivalents per day.
Criterion Antipsychotic medications are prescribed in a dosage range of 300-600 mg CPZ equivalents per day.
Conformance rate Percent of patients, on one antipsychotic medication, for whom the current dosage is in the 300-600 CPZ equivalent range. wach (1998b) reported that 92% of outpatients were treated with an antipsychotic. Using administrative data from a Veterans Affairs health center, Chen, et al. (2000) found a 77% prescribing rate, perhaps reflecting patient, rather than physician, adherence rates, since only prescriptions filled were measured and not prescriptions written. Only 43% of patients in our sample received the recommended antipsychotic maintenance dose of 300-600 mg CPZ equivalents, while 26% were below treatment guidelines and 32% above. Similar results were reported in the PORT evaluation (Lehman and Steinwachs, 1998b) where 29.1% of patients were in the recommended range; 31.9% above and 39.1% below. In the VA clinic study Chen et al. (2000) found 53% of patients were within a range of 300-1000 mg CPZ equivalents, with 42% below 300 CPZ equivalents and 5% above 1000 mg. CPZ equivalents. (Similarly, 8% of our patients were receiving antipsychotic doses above 1000 mg CPZ equivalents; 9 of these 14 patients were on clozapine.) Young, et al. (1998) , using a combined patient interview/chart review, reported that 79% of patients in two public clinics received inappropriate management of medication side effects (akathisia, parkinsonism, and TD). Of the forty-six CMH patients who met our criteria for severe TD (AIMS ≥3) nearly two-thirds (63%) were being treated with an atypical antipsychotic, 24% (11) with clozapine.
Median
Eighty-three patients (26.9%) in our study had a documented presence of residual positive psychotic symptoms. Seventy of those (84%) received at least one of the recommended adjunctive treatments. We suspect that conformance rates for this criterion will increase as more studies addressing the use of adjunctive agents in refractory psychosis are published.
In our medical record review, we found that many charts lacked sufficient documentation of negative symptoms, medication side effects, and comorbid conditions to assess adherence to guidelines related to these key aspects of treatment. Similar deficiencies in the necessary documentation have been reported in a variety of treatment settings (Chen, Nadkarni, Levin, Miller, Tu, Ivanco, and Li, 2000; Dassori, Chiles, and Swenson-Britt, 2000; Lehman and Steinwachs, 1998b; Young, Sullivan, Burnam, and Brook, 1998) . It is impossible to know whether information about symptomatology was missing because it was not present on evaluation or not documented. Young et al. (1998) suggest the latter: they found that half of the symptoms and less than fifteen percent of medication side effects revealed by patients in a structured interview were actually recorded in the medical record.
